Daratumumab plus bortezomib and dexamethasone (Dara‐ VD ) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study
British Journal of Haematology · 2026-06 · 208 (6) · 2096-2103
DOI: 10.1111/bjh.70445 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, online erschienen am 18.03.2026. Verfasst von Gao Xue-Min und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Peopl…. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences(CIFMS), National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a prospective phase 2 trial including 20 stage IIIA and 20 stage IIIB patients. The long‐term follow‐up results are reported here. The 24‐month haematological complete response (CR) and very good partial response (VGPR) rate were 52.5% and 12.5% respectively. Organ responses improved after 12 months; the 24‐month cardiac CR and VGPR rates were 15.0% and 35.0%. After a median follow‐up of 50.9 months, 16 patients died and 10 patients had progressive diseases. The median overall survival (OS) had not been reached in either group, with a 4‐year OS rate of 60.0% (95% confidence interval [CI]: 45.2%–75.2%). The median event‐free survival (EFS) was 33.5 months (95% CI 21.0–46.0 months), with a 4‐year EFS rate of 37.5% (95% CI: 24.3–54.7). No significant difference in OS or EFS was observed between stage IIIA and IIIB patients. In conclusion, the strong anti‐plasma cell regimen Dara‐VD provides comparable long‐term responses and prognosis for Mayo stage IIIB patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
- Center for Rare Diseases, State Key Laboratory of Complex, Severe, and Rare Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
ORCID-Profile: Gao Xue-Min, Xu Chengyang, Xu Yi, Li Jian
Förderung
- National Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences(CIFMS)
- National High Level Hospital Clinical Research Funding
- Peking Union Medical College Hospital Talent Cultivation Program
- Xi'an Janssen Pharmaceutical Ltd., Beijing, China
Zitieren
APA
Xue-Min, G., Chengyang, X., Ya-Juan, G., Ai, G., Yi, X., Long, C., Kai-Ni, S., & Jian, L. (2026). Daratumumab plus bortezomib and dexamethasone (Dara‐ VD ) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study. British Journal of Haematology, 208(6), 2096-2103. https://doi.org/10.1111/bjh.70445
Vancouver
Xue-Min G, Chengyang X, Ya-Juan G, Ai G, Yi X, Long C, et al. Daratumumab plus bortezomib and dexamethasone (Dara‐ VD ) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study. British Journal of Haematology. 2026;208(6):2096-2103. doi:10.1111/bjh.70445
BibTeX
@article{XueMin2026,
author = {Xue-Min, Gao and Chengyang, Xu and Ya-Juan, Gao and Ai, Guan and Yi, Xu and Long, Chang and Kai-Ni, Shen and Jian, Li},
title = {Daratumumab plus bortezomib and dexamethasone (Dara‐ VD ) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {6},
pages = {2096--2103},
doi = {10.1111/bjh.70445}
}
EUVIMED